title: Treatment of hypertensive patients with diabetes: beyond blood pressure control and focus on manidipine.
abstract: Renin-angiotensin system inhibitors should be considered as the first-line therapy in the treatment of patients with hypertension and diabetes. However, most of the diabetic subjects with hypertension require at least two drugs to achieve blood pressure targets. The ACCOMPLISH trial suggested that the best combination in the treatment of high-risk hypertensive patients should include a renin-angiotensin system inhibitor and a dihydropyridine. However, not all dihydropyridines block the same receptors. Those dihydropyridines that block T-type calcium channel blockers may provide additional advantages. A number of studies suggest that compared with amlodipine, manidipine have the same antihypertensive efficacy, but with a lesser risk of ankle edema. In addition, manidipine, but not amlodipine, significantly reduces urinary albumin excretion rates.
authors.affiliation: Hospital Universitario Mutua Terrassa, Barcelona, Spain.
authors.forename: Margarita
authors.initials: M
authors.lastname: Saiz Satjes
authors.affiliation: Outpatient Hypertension Clinic, University Hospital of Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, Spain.
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Martinez-Martin
mesh_terms: D017311:Amlodipine / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003920:Diabetes Mellitus; D004095:Dihydropyridines / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D009578:Nitrobenzenes; D010879:Piperazines
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D009578:Nitrobenzenes; D010879:Piperazines; D017311:Amlodipine; C054218:manidipine
keywords: amlodipine; diabetes; hypertension; manidipine; microalbuminuria